8-K current report · filed Aug 5, 2026

LIFECORE BIOMEDICAL, INC. DE (LFCR) 8-K Current Report: August 5, 2026

Item 7.01Item EX-99.1Item EX-99.2Item 2.02LFCR overview

Short answer

LIFECORE BIOMEDICAL, INC. DE (LFCR) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Fiscal second-quarter and six-month results ended June 30, 2026 announced by Lifecore Biomedical.

LIFECORE BIOMEDICAL, INC. DE 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal second-quarter and six-month results ended June 30, 2026 announced by Lifecore Biomedical
  • Investors should review Exhibit 99.1 for revenue, profitability, liquidity and outlook details

Item 7.01 · Regulation FD Disclosure

  • Investor presentation posted August 5, 2026, providing shareholders with updated company information
  • Exhibit 99.2 contains the substantive presentation materials for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 revenue $34.2M, net loss $(6.2)M, and Adjusted EBITDA $8.6M
  • 2026 guidance reaffirmed: revenue $120-$125M and Adjusted EBITDA $20.5-$25M
  • Liquidity $38.8M at June 2026, including $17.2M cash and $21.6M revolver availability
  • Six new Q2 programs and 13 wins over 12 months strengthen future commercial visibility
  • Pipeline targets 11 launches in 2027-2028 with estimated $150-$200M incremental peak revenue potential, not risk-adjusted

Item EX-99.2 · Exhibit EX-99.2

  • Q2 2026 revenue $34.2M, net loss $6.2M, and Adjusted EBITDA $8.6M, highlighting strong profitability despite GAAP losses
  • 2026 guidance reaffirmed: revenue $120M-$125M and Adjusted EBITDA $20.5M-$25M
  • Liquidity $38.8M at June 2026, including $17.2M cash and $21.6M revolver availability
  • Six new programs signed in Q2, including two commercial-stage programs, with 13 wins over 12 months
  • Growth roadmap targets approximately 12% revenue CAGR and over 25% Adjusted EBITDA margins by year-end 2029

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other LIFECORE BIOMEDICAL, INC. DE 8-K filings

Get the next LFCR 8-K as it lands

Follow LFCR for push alerts, or ask the research agent what this filing means.